NAS:LIMN (USA)
Â
Class A Ordinary Shares
$
0.11
+0.00030 (+0.29%)
10:08 PM EST
Business Description
Liminatus Pharma Inc
NAICS : 541720
SIC : 2834
ISIN : US53271X1081
Share Class Description:
LIMN: Class A Ordinary SharesTotal Employee Number:
1Description
Liminatus Pharma Inc is a clinical-stage biopharmaceutical company engaged in developing cancer therapies and treatments. The company is developing a next generation CD47 immune checkpoint inhibitor that enables cancer cells to evade detection by the immune system. Anti-CD47 monoclonal antibodies generally induce anemia and thrombocytopenia due to their binding to red blood cells and platelets. The Liminatus CD47 mAb has shown to preferentially bind to immune cells, but not to red blood cells and platelets and does not induce hemolysis. The clinical candidate is currently in the late preclinical stage.
Financial Strength
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 1.32 | |||||
Equity-to-Asset | -0.05 | |||||
Debt-to-Equity | -10.85 | |||||
Debt-to-EBITDA | -0.13 | |||||
Piotroski F-Score | N/A/9 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | -59.4 | |||||
3-Year EPS without NRI Growth Rate | -58.4 | |||||
3-Year FCF Growth Rate | -133.5 | |||||
3-Year Book Growth Rate | 4.4 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 37.83 | |||||
9-Day RSI | 41.94 | |||||
14-Day RSI | 42.95 | |||||
3-1 Month Momentum % | -48.16 | |||||
6-1 Month Momentum % | -82.67 | |||||
12-1 Month Momentum % | -98.69 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 0.96 | |||||
Quick Ratio | 0.96 | |||||
Cash Ratio | 0.66 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -1.3 | |||||
Shareholder Yield % | 56.57 |
Profitability Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
ROA % | -671.53 | |||||
ROIC % | -109.75 | |||||
3-Year ROIIC % | 1.72 | |||||
ROC (Joel Greenblatt) % | -88240.54 | |||||
Moat Score | 3 | |||||
Tariff Resilience Score | 8 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
EV-to-EBIT | -0.61 | |||||
EV-to-EBITDA | -0.61 | |||||
EV-to-FCF | -0.56 | |||||
Earnings Yield (Greenblatt) % | -163.93 | |||||
FCF Yield % | -165.56 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:LIMN
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Liminatus Pharma Inc Executives
DetailsGF Valueâ„¢
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | |||
| EPS (TTM) ($) | -0.44 | ||
| Beta | - | ||
| 3-Year Sharpe Ratio | - | ||
| 3-Year Sortino Ratio | - | ||
| Volatility % | 72.18 | ||
| 14-Day RSI | 42.95 | ||
| 14-Day ATR ($) | 0.020598 | ||
| 20-Day SMA ($) | 0.119595 | ||
| 12-1 Month Momentum % | -98.69 | ||
| 52-Week Range ($) | 0.095 - 8.06 | ||
| Shares Outstanding (Mil) | 67.16 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 9999 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Liminatus Pharma Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Liminatus Pharma Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Third quarter earnings results for 2026 | 2026-11-13 | In 107 days | ||
| Second quarter earnings results for 2026 | 2026-10-06 | In 69 days | ||
| General meeting for 2026 | 2026-08-03 10:30 | In 6 days | ||
| First quarter earnings results for 2026 | 2026-05-15 | 0.18 (-1.66%) | ||
| Annual report for 2025 | 2026-03-31 | 0.18 (-2.69%) | ||
| Fourth quarter earnings results for 2025 | 2026-03-31 | 0.18 (-2.69%) | ||
| Third quarter earnings results for 2025 | 2025-11-14 | 1.07 (-8.55%) | ||
| Second quarter earnings results for 2025 | 2025-10-06 | 1.73 (-8.95%) | ||
| First quarter earnings results for 2025 | 2025-06-02 | 5.43 (-5.40%) |
Show
Entries
Liminatus Pharma Inc Frequently Asked Questions
What is Liminatus Pharma Inc(LIMN)'s stock price today?
The current price of LIMN is $0.11. The 52 week high of LIMN is $8.06 and 52 week low is $0.10.
When is next earnings date of Liminatus Pharma Inc(LIMN)?
The next earnings date of Liminatus Pharma Inc(LIMN) is 2026-10-06 Est..
Does Liminatus Pharma Inc(LIMN) pay dividends? If so, how much?
Liminatus Pharma Inc(LIMN) does not pay dividend.
Guru Commentaries on NAS:LIMN
No articles.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Articles on Liminatus Pharma Inc
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers